Checkmate Pharmaceuticals, Inc.
DelistedCIK 1651431fmd_0PM3NGDBFW7YRJ96VG1HSKER9DManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2019 to Mar 31, 2022, 12 periods
| Line item | FY2019 | FY2020 | FY2021 |
|---|---|---|---|
| Research and development | 24 | 27 | 46 |
| Total operating expenses | 29 | 37 | 61 |
| Operating income | (29) | (37) | (61) |
| Interest and investment income | 0 | 0 | 0 |
| Other non-operating income (expense) | 1 | (0) | 0 |
| Net income | (28) | (37) | (61) |
| Net income to common shareholders | (35) | (43) | (61) |